Biogen Inc.’s Tecfidera (dimethyl fumarate) is continuing its tortuous trek across Europe’s health technology assessment landscape, hitting its latest hurdle in Germany where the country’s junior HTA body, IQWiG, says a lack of appropriate data makes it impossible to determine whether the relapsing-remitting multiple sclerosis pill provides any added benefit over existing therapies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?